NEW YORK (GenomeWeb) – Adaptive Biotechnologies said today that it has agreed to use its technology to measure the efficacy of Janssen's Darzalex (daratumumab) in multiple myeloma (MM).

Under the terms of the collaboration, Adaptive will use its NGS-based ClonoSeq assay to measure minimal residual disease (MRD) in MM patients treated with Darzalex in ongoing clinical trials. The two companies hope to demonstrate the clinical utility of monitoring MRD as a way of assessing the medication's effectiveness.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.